Gardiquimod

CHF 60.00
In stock
AG-CR1-3583-M0055 mgCHF 60.00
AG-CR1-3583-M02525 mgCHF 210.00
More Information
Product Details
Synonyms 1-(4-Amino-2-ethylaminomethylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol
Product Type Chemical
Properties
Formula

C17H23N5O

MW 313.4
CAS 1020412-43-4
Source/Host Chemicals Synthetic.
Purity Chemicals ≥98%
Appearance White to off-white powder.
Solubility Soluble in DMSO (30mg/ml), dioxane (5mg/ml), methanol (30mg/ml) or acetonitrile (2mg/ml).
InChi Key FHJATBIERQTCTN-DZQCGVKKCV
Smiles CCNCC1=NC2=C(N1CC(C)(C)O)C1=C(C=CC=C1)N=C2N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Stock solutions are stable for at least 3 months when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Immune response modifier.
  • Antiviral and antitumor compound
  • Selective ligand for human or mouse Toll-like receptor 7 (TLR7).
  • Induces the activation of NF-κB in HEK 293 cells expressing TLR7 at 0.1µg/ml. 10 times more active than Imiquimod (Prod. No. AG-CR1-3569).
  • At high concentrations (3µg/ml) slightly activates TLR8.
  • Shows adjuvant activity to increase the effectiveness of vaccines.
Product References
  1. Double-Stranded RNA Induces an Antiviral Defense Status in Epidermal Keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-Mediated Differential Signaling: B.N. Kalali, et al.; J. Immunol. 181, 2694 (2008)
  2. Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod: J. Zhu, et al.; Mol. Immunol. 45, 3238 (2008)
  3. Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline: N.M. Shukla, et al.; Bioorg. Med. Chem. Lett. 19, 2211 (2009)
  4. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate: S.L. Baldwin, et al; Vaccine 27, 3063 (2009)
  5. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells: N.A. Forward, et al.; J. Leukoc. Biol. 87, 117 (2010)
  6. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice: F. Ma, et al.; Cell Mol. Immunol. 7, 381 (2010)
  7. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity: J. Du, et al.; Vaccine 28, 6273 (2010)
  8. TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation: D.E. Tuipulotu, et al.; Antimicrob. Agents Chemother., ahead of print (2018)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.